Last patient enrolled in study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of OUD

UPPSALA, Sweden, Oct. 28, 2022. Orexo AB (publ.), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA as part of a clinician supervised medication-assisted treatment program for the treatment of opioid u

FDA Approves Tecvayli

FDA Approves Tecvayli

Mylan Institutional LLC, a Viatris Company, Issues a Voluntary Recall of One Lot of Octreotide Acetate Injection, 500 mcg/mL, Due to Glass Particulates in a Syringe

Acupuncture May Ease Anxiety in Patients With Parkinson Disease

Acupuncture May Ease Anxiety in Patients With Parkinson Disease THURSDAY, Sept. 29, 2022 -- Acupuncture may help treat anxiety in patients with Parkinson disease and anxiety, according to a study published online Sept. 21 in JAMA Network Open. Jing-qi

FDA Approves New Treatment Option for Patients with ALS

FDA Approves New Treatment Option for Patients with ALS SILVER SPRING, Md., Sept. 29, 2022. The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), com

FDA Approves Omlonti

FDA Approves Omlonti FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension EMERYVILLE, Calif. & UBE, Japan--(BUSINESS WIRE) September 26, 20